What is the long-term trend for Esperion Therapeutics's operating lease liability payments - 2029 (lessee)?

Over 3 years (2022 to 2025), Esperion Therapeutics's operating lease liability payments - 2029 (lessee) has grown at a -100.0% compound annual growth rate (CAGR), from $169K to $0.

Esperion Therapeutics ESPR Operating Lease Liability Payments - 2029 (Lessee)

Operating Lease Liability Payments - 2029 (Lessee) at other companies

Lexicon PharmaceuticalsLXRX

——

Nurix Therapeutics, Inc.NRIX

——

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Revenue$80.1M+23.2%

Operating income-$6.6M+70.2%

Net income-$25.2M+37.7%

EPS (diluted)-$0.10+52.4%

Balance sheet

See full

Cash & equivalents$156.2M+36.2%

Total debt$155.2M+6.1%

Total equity-$307.9M+27.8%

Total assets$462.5M+42.7%

Cash flow

See full

Operating cash flow-$27.7M-22.5%

CapEx$189.0K—

Free cash flow-$27.9M-23.3%

Valuation

See full

Market cap$811.73M+283%

Enterprise value$810.81M+233%

P/S1.9×+1.1×

Profitability

See full

Operating margin18.1%+12.7pp

Net margin-34.8%+8.0pp

FCF margin-30.7%—

Returns & leverage

See full

Return on equity-260.8%—

Debt / equity0.8×—

Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive.

The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's operating lease liability payments - 2029 (lessee).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Esperion Therapeutics's operating lease liability payments - 2029 (lessee)?: Esperion Therapeutics (ESPR) reported operating lease liability payments - 2029 (lessee) of $0 in Q4 2025.
What is the long-term trend for Esperion Therapeutics's operating lease liability payments - 2029 (lessee)?: Over 3 years (2022 to 2025), Esperion Therapeutics's operating lease liability payments - 2029 (lessee) has grown at a -100.0% compound annual growth rate (CAGR), from $169K to $0.